Home › Funds › Frazier Life Sciences Management, L.P. › CYTK

Frazier Life Sciences Management, L.P. position in CYTK

CYTOKINETICS INC COM NEW · Health Care

Frazier Life Sciences Management, L.P. reported holding 1,159,879 shares of CYTK (CYTOKINETICS INC COM NEW) in its Q2 2026 13F filing — a position valued at US$98.8M, representing 2.15% of its reported portfolio and ranking #13 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed CYTK holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

Latest position (Q2 2026)1.16M sh
Reported value held$98.81M
Portfolio Weight2.15%
First reportedQ2 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Frazier Life Sciences Management, L.P.'s CYTK position evolved

Frazier Life Sciences Management, L.P. first disclosed a stake in CYTK in Q2 2025 at 554,731 shares (US$18.3M). The position peaked in Q2 2026 at 1,159,879 shares, worth US$98.8M. Across 5 filings, Frazier Life Sciences Management, L.P. increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,159,879 shares valued at US$98.8M. Notable position changes include a 61% increase in Q3 2025 (shares rose 16% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 554.73K $18.33M New
Q3 2025 890.45K $48.94M Add
Q4 2025 934.64K $59.39M Add
Q1 2026 1.16M $76.45M Add
Q2 2026 1.16M $98.81M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CYTK and 13F data

CYTK (CYTOKINETICS INC COM NEW) is a Health Care company. 51 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CYTK

All CYTK fund holders →

FAQ

How long has Frazier Life Sciences Management, L.P. held CYTK?

Frazier Life Sciences Management, L.P. has disclosed CYTK holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

What is Frazier Life Sciences Management, L.P.'s current position in CYTK?

As of Q2 2026, Frazier Life Sciences Management, L.P. holds 1.16M shares of CYTK (CYTOKINETICS INC COM NEW), valued at $98.81M, representing 2.15% of its reported portfolio and ranking #13.

Has Frazier Life Sciences Management, L.P. been buying or selling CYTK?

In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. held unchanged its position in CYTK. The position peaked in Q2 2026 at 1.16M shares.

Which other funds hold CYTK?

Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 51 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.